Abstract
Tuberculosis (TB) remains a main hurdle for national programs due to increase in drug resistance to antitubercular drugs. World Health Organization (WHO)-endorsed Line Probe Assay, Genotype MTBDRsl Ver 2.0, gives opportunity for rapid diagnosis and molecular characterization of different mutations in drug targets of fluoroquinolone (FQ) and second-line injectable drugs (SLID). We, retrospectively, analyzed the data of Genotype MTBDRsl Ver 2.0 from January 2018 to June 2018. A total of 863 isolates of Mycobacterium tuberculosis, 687 rifampicin resistant and 176 isoniazid resistant only, were screened for drug resistance in FQ and SLID. All the isolates were tested for Genotype MTBDRsl Ver 2.0 according to the manufacturer’s instructions. The FQ and SLID resistance were detected in 295 (34.2%) and 70 (8.1%) isolates, respectively. Among newly diagnosed and followup rifampicin-resistant TB (RR TB) patients, the FQ resistance was 25.8% and 44.5%, respectively. The most common mutation (42.7%) in FQ-resistant isolates was MUT3C in gyrA gene. Both SLID and FQ resistance were detected in 59 (6.8%) RR TB isolates. The mono SLID resistance was detected in 12 (1.7%) isolates of RR TB. Genotype MTBDRsl Ver 2.0 assay is a rapid and important tool for the diagnosis and molecular characterization of second-line drug resistance under programmatic conditions.
Highlights
Drug-resistant tuberculosis (TB) remains a main hurdle for national tuberculosis control programs
Genotype MTBDRsl Ver 2.0, line probe assays (LPAs) for fluoroquinolone (FQ) and second-line injectable drugs (SLID) drug resistance detection based on reverse hybridization technology, was endorsed by World Health Organization (WHO) for rapid detection of second-line drug resistance [3]
Genotype MTBDRsl Ver 2.0 assay is included as a frontline test for second-line resistance detection in MDR TB/resistant TB (RR TB) or isoniazid-
Summary
Drug-resistant tuberculosis (TB) remains a main hurdle for national tuberculosis control programs. The second-line drug resistance detection is a challenge due to very limited WHOendorsed tests [2]. The nucleic acid amplification methods have very high sensitivity and specificity and recommended for detection of drug resistance to first-line drugs, mainly rifampicin and isoniazid. Genotype MTBDRsl Ver 2.0, LPA for fluoroquinolone (FQ) and second-line injectable drugs (SLID) drug resistance detection based on reverse hybridization technology, was endorsed by WHO for rapid detection of second-line drug resistance [3]. The assay includes 27 probes based on reverse hybridization technology for detection of FQ and aminoglycoside drug resistance. Genotype MTBDRsl Ver 2.0 assay is included as a frontline test for second-line resistance detection in MDR TB/RR TB or isoniazid-. We retrospectively analyzed the resistance pattern and molecular characterization of FQ and aminoglycoside in MDR TB/RR TB or isoniazid-resistant TB
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
